HomeCompareADVM vs O

ADVM vs O: Dividend Comparison 2026

ADVM yields 45.87% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADVM wins by $283.4K in total portfolio value
10 years
ADVM
ADVM
● Live price
45.87%
Share price
$4.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$317.6K
Annual income
$60,065.20
Full ADVM calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ADVM vs O

📍 ADVM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADVMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADVM + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADVM pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADVM
Annual income on $10K today (after 15% tax)
$3,899.08/yr
After 10yr DRIP, annual income (after tax)
$51,055.42/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, ADVM beats the other by $46,718.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADVM + O for your $10,000?

ADVM: 50%O: 50%
100% O50/50100% ADVM
Portfolio after 10yr
$175.9K
Annual income
$32,583.97/yr
Blended yield
18.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ADVM
No analyst data
Price Target
$4.83
+10.8% upside vs current
Range: $4.00 — $5.50
Altman Z
-32.7
Piotroski
1/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADVM buys
0
O buys
0
No recent congressional trades found for ADVM or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADVMO
Forward yield45.87%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$317.6K$34.2K
Annual income after 10y$60,065.20$5,102.74
Total dividends collected$248.2K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst price target$4.83$64.00

Year-by-year: ADVM vs O ($10,000, DRIP)

YearADVM PortfolioADVM Income/yrO PortfolioO Income/yrGap
1← crossover$15,287$4,587.16$10,818$608.16+$4.5KADVM
2$22,911$6,553.70$11,787$741.68+$11.1KADVM
3$33,694$9,179.50$12,946$911.00+$20.7KADVM
4$48,670$12,616.75$14,345$1,127.94+$34.3KADVM
5$69,108$17,032.01$16,056$1,409.05+$53.1KADVM
6$96,549$22,602.46$18,171$1,777.83+$78.4KADVM
7$132,818$29,511.17$20,820$2,268.21+$112.0KADVM
8$180,057$37,941.48$24,188$2,929.90+$155.9KADVM
9$240,732$48,070.97$28,533$3,837.11+$212.2KADVM
10$317,648$60,065.20$34,235$5,102.74+$283.4KADVM

ADVM vs O: Complete Analysis 2026

ADVMStock

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Full ADVM Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ADVM vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADVM vs SCHDADVM vs JEPIADVM vs KOADVM vs MAINADVM vs STAGADVM vs ADCADVM vs NNNADVM vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.